ClinicalTrials.gg
RecruitingNCT07247162LINC CAREUpdated Nov 2, 2026

Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome

A Phase 4 interventional study of Osilodrostat and Placebo in Hypertension, Hypercortisolemia and Cushing Syndrome, sponsored by RECORDATI GROUP. Recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by RECORDATI GROUP · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.
Updated Oct 28, 2026Now RecruitingFirst site in United States+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
63
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 2,031 studies in Hypertension with a site in United States — 272 open to participants now, 369 under way, 16 of them phase 3. Hypertension · United States.

Planned enrollment
1,052nd of 1,779
63 · median 100
Started
2026
with 100 others
Phase 4
188 of 2,031
13 open now
Primary completion
2028-05
later than 256 of 367 live
Registered
1,941st of 2,031
by date

Among the 2,031 studies in Hypertension with a site in United States, this one is the 1,052nd largest by planned enrollment of the 1,779 interventional ones that give a count, is one of 101 that started in 2026, is one of 188 in phase 4, reaches primary completion later than 256 of the 367 other live ones, and was the 1,941st registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 913 are open to participants now.

Browse Hypertension studies →

Open to participants now

272 of the 2,031 studies in Hypertension with a site in United States are open now. Recruiting first, the newest first:

266 more — sign in →

All 272 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 563 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (36%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,031 studies in Hypertension with a site in United States, or all of them as a file.
02

Study summary

Osilodrostat has proven to be a safe and efficacious treatment for patients with CS. Demonstrating normalisation of hypercortisolaemia and in patients with hypertension and/or dysglycaemia clinically relevant and statistically significant reductions in blood pressure and glycaemia. This study aims at providing additional evidence on the safety, efficacy and appropriate dosing of osilodrostat in patients with CS, who have hypertension.

03

Conditions studied

  • Hypertension
  • Hypercortisolemia
  • Cushing Syndrome

Keywords

  • osilodrostat
  • hypertension
  • hypercolesterolaemia
  • cushing's syndrome
04

Who can participate

The criteria were revised on the registry on Oct 28, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female ≥ 18 years of age
  2. Able to provide and have provided signed written prior to study participation
  3. Diagnosis of endogenous Cushing's Syndrome
  4. mUFC values from two 24h urinary collections > and ≤ 2x ULN
  5. Participants with uncontrolled hypertension on stable doses of BP lowering medications (for at least 4 weeks); qualifying BP measurements by ABPM taken prior to randomisation defined as: Average of 24h ABPM SBP ≥ 135 or DBP ≥ 85 mmHg
  6. Participants under replacement therapy can be recruited only if this therapy has been already stopped for at least seven days or 5 half-lives prior to screening, whichever was longer
  7. Not taking any drug therapy for CS. The following minimum periods without these medications need to be completed before baseline assessments:

    1. Steroidogenesis inhibitors (e.g. ketoconazole, metyrapone): 1 week
    2. Mifepristone: 3 weeks
    3. SC Pasireotide: 1 week
    4. Pasireotide LAR: 3 months
    5. Cabergoline: 4 weeks
  8. Able to take oral medication and be willing to comply with the requirements of the study

Exclusion criteria

Exclusion Criteria:

  1. Previously treated with osilodrostat less than 12 weeks prior to start of screening
  2. Known to osilodrostat
  3. Presence of any severe and/or uncontrolled medical condition or other conditions that could affect participation in the study
  4. Participants who are scheduled for a surgery to treat CS within 32 weeks of randomisation to the study drug
  5. Presence of a known "long term" history of both hypertension and diabetes (defined as both hypertension and diabetes diagnosed >10 years prior to the initial diagnosis of endogenous CS)
  6. History of cyclic CS with fluctuating clinical manifestations
  7. Participants with pseudo-CS
  8. Participants with compression of the optic chiasm due to a macroadenoma or participants at high risk of compression of the optic chiasm (tumour within 2 mm of optic chiasm)
  9. Participants who have undergone pituitary or adrenal surgery for Cushing's syndrome within 3 months prior to screening.
  10. Pituitary radiation therapy within 3 years of screening
  11. Ectopic ACTH syndrome or adrenocortical carcinoma with a of \<3 years or receiving chemotherapy
  12. Having received prior mitotane treatment
  13. Participants who are shift workers or have conditions that can affect the measurement of late-night salivary cortisol (LNSC) or the LDDST
  14. Poorly controlled diabetes mellitus with a baseline > 10.5%. Participants receiving glucose lowering medications must be on stable doses for at least 4 weeks prior screening.
  15. Participants who are hypothyroid and not on adequate replacement therapy
  16. History of major surgery/surgical therapy for any cause within 4 weeks before entering the study. Participants should have recovered from the surgery and be in good clinical condition before entering the study
  17. Presence of bradycardia and/or -related exclusion criteria
  18. Total > 1.5 x and or AST > 3 x ULN
  19. Participation in any clinical investigation within 4 weeks prior to screening or longer if required by local regulation (Use of an drug within 4 weeks prior to dosing)
  20. Occurrence of any significant acute illness within 3 weeks prior to dosing/randomisation
  21. Female participants who are pregnant, intending to become pregnant or breastfeed during the study or lactating, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test
  22. Women of (WOCBP) who are unwilling to use highly effective methods
  23. Potentially unreliable or vulnerable participants (e.g. person kept in detention) and those judged by the Investigator to be unsuitable for the study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
63 participants (estimated)

Study arms

  • Experimental
    LCI699 (osilodrostat)

    1 mg QOD

    Drug: Osilodrostat

  • Placebo comparator
    Placebo

    matching placebo

    Drug: Placebo

Interventions

  • Osilodrostat tablets 1 mg and 5 mg for oral useOsilodrostat tablets 1 mg and 5 mg for oral use.During the 18-week titration phase, the dose of the medication will be titrated every 3 weeks based on the cortisolaemic and clinical response to treatment. An independent endocrinologist titration committee will be applied to provide recommendations on dose-titration based on biochemical and clinical response. At the end of the 18-week dose titration phase, participants will enter a 12-week dose maintenance phase, which is also blinded. They will continue with the dose they were receiving at the end of the dose titration phase, unless there is a need to down-titrate or to stop the study medication for safety purposes.

    Also known as: isturisa

  • DrugPlacebo

    matching placebo

06

What researchers measure

Primary outcomes

  1. To evaluate the efficacy of osilodrostat on the proportion of participants with normalization of urinary-free cortisol (UFC)

    Normalization status for each participant at Week 30 of treatment with osilodrostat or placebo, based on the mean of UFC concentrations from two 24-hour urine collections, with normalization defined as ≤1× the upper limit of normal (ULN).

    Time frame: 30 weeks

Secondary outcomes

  1. Percentage of Participants With Blood Pressure Response by 24-Hour Ambulatory Blood Pressure Monitoring (ABPM) at Week 30 (key secondary)

    Blood pressure (BP) responder status is assessed by 24-hour ABPM. This measure will check the % of participants that are responders. A participant is a responder if mean systolic and/or diastolic BP decreases by at least 5 mmHg from baseline, without worsening of either and without any modification in antihypertensive medication attributable to worsening hypertension. Participants without a valid ABPM assessment at Week 30 are classified as non-responders.

    Time frame: Week 30

  2. Percentage of Participants With Hypocortisolism-Related Adverse Events (Overall)

    Percentage of participants with at least one hypocortisolism-related adverse event (AE) during the treatment period.

    Time frame: Week 30

  3. Percentage of Participants With Glucocorticoid Withdrawal Syndrome

    Percentage of participants with glucocorticoid withdrawal syndrome, a category of hypocortisolism-related AEs, during the treatment period.

    Time frame: Week 30

  4. Percentage of Participants With Confirmed Adrenal Insufficiency

    Percentage of participants with confirmed adrenal insufficiency, a category of hypocortisolism-related AEs, during the treatment period.

    Time frame: Week 30

  5. Percentage of Participants With Glycemic Response at Week 30 in Participants With High-Risk Dysglycemia

    Assessed in participants with high-risk dysglycemia at baseline (HbA1c \>=6.0%). A glycemic responder has a reduction of at least 25% from baseline in glucose area under the curve (AUC) during an oral glucose tolerance test (OGTT), without the addition of, or an increase in the dose of, glucose-lowering medications.

    Time frame: baseline and Week 30

  6. Percentage of Participants With Glycemic Response at Week 21 in Participants With High-Risk Dysglycemia

    Assessed in participants with high-risk dysglycemia at baseline (HbA1c \>=6.0%). A glycemic responder has a reduction of at least 25% from baseline in glucose area under the curve (AUC) during an oral glucose tolerance test (OGTT), without the addition of, or an increase in the dose of, glucose-lowering medications.

    Time frame: Baseline and Week 21

  7. Percentage of Participants With Body Weight Response at Week 30

    A body weight responder has a decrease of at least 5% from baseline in body weight, without the addition of, or an increase in the dose of, weight-lowering medications.

    Time frame: baseline and Week 30

  8. Percentage of Participants With Body Weight Response at Week 21

    A body weight responder has a decrease of at least 5% from baseline in body weight, without the addition of, or an increase in the dose of, weight-lowering medications.

    Time frame: baseline and Week 21

  9. Change From Baseline in Systolic Blood Pressure (SBP) by 24-Hour ABPM at Week 30

    Change from baseline in mean 24-hour SBP measured by ambulatory blood pressure monitoring (ABPM). Change = value at Week 30 minus baseline value.

    Time frame: Baseline, Week 30

  10. Change From Baseline in Systolic Blood Pressure (SBP) by 24-Hour ABPM at Week 21

    Change from baseline in mean 24-hour SBP measured by ambulatory blood pressure monitoring (ABPM). Change = value at Week 21 minus baseline value.

    Time frame: baseline and Week 21

  11. Change From Baseline in Glucose AUC During OGTT at Week 30 in Participants With High-Risk Dysglycemia

    Assessed in participants with high-risk dysglycemia at baseline (HbA1c \>=6.0%). Change from baseline in glucose area under the curve (AUC) during an oral glucose tolerance test (OGTT). Change = value at Week 30 minus baseline value.

    Time frame: baseline and Week 30

  12. Change From Baseline in Glucose AUC During OGTT at Week 21 in Participants With High-Risk Dysglycemia

    Assessed in participants with high-risk dysglycemia at baseline (HbA1c \>=6.0%). Change from baseline in glucose area under the curve (AUC) during an oral glucose tolerance test (OGTT). Change = value at Week 21 minus baseline value.

    Time frame: baseline and Week 21

  13. Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 30 in Participants With High-Risk Dysglycemia

    Assessed in participants with high-risk dysglycemia at baseline (HbA1c \>=6.0%). Change = HbA1c value at Week 30 minus baseline value.

    Time frame: baseline and Week 30

  14. Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 21 in Participants With High-Risk Dysglycemia

    Assessed in participants with high-risk dysglycemia at baseline (HbA1c \>=6.0%). Change = HbA1c value at Week 21 minus baseline value.

    Time frame: baseline and Week 21

  15. Change From Baseline in 2-Hour Postprandial Glucose at Week 30 in Participants With High-Risk Dysglycemia

    Assessed in participants with high-risk dysglycemia at baseline (HbA1c \>=6.0%). Change = 2-hour postprandial glucose value at Week 30 minus baseline value.

    Time frame: Baseline, Week 30

  16. Change From Baseline in 2-Hour Postprandial Glucose at Week 21 in Participants With High-Risk Dysglycemia

    Assessed in participants with high-risk dysglycemia at baseline (HbA1c \>=6.0%). Change = 2-hour postprandial glucose value at Week 21 minus baseline value.

    Time frame: baseline and Week 21

  17. Change From Baseline in Fasting Plasma Glucose Over Time in Participants With High-Risk Dysglycemia

    Assessed in participants with high-risk dysglycemia at baseline (HbA1c \>=6.0%). Change from baseline in fasting plasma glucose (FPG) at each scheduled visit.

    Time frame: Up to Week 30

  18. Change From Baseline in Body Weight Over Time

    Change from baseline in body weight at each scheduled visit.

    Time frame: Up to Week 30

  19. Participants (n) With Adverse Events

    Frequency of participants with AEs, by treatment group, during the treatment period.

    Time frame: Up to Week 30

  20. Participants (%) With Adverse Events

    percentage of participants with AEs, by treatment group, during the treatment period.

    Time frame: Up to Week 30

  21. Change From Baseline in Laboratory Values

    Change from baseline in safety laboratory values at each scheduled visit.

    Time frame: Up to Week 30

  22. Change From Baseline in Electrocardiogram (ECG) Parameters

    Change from baseline in ECG readings at each scheduled visit.

    Time frame: Up to Week 30

  23. Change From Baseline in Vital Signs

    Change from baseline in vital signs at each scheduled visit.

    Time frame: Up to Week 30

  24. Shift in American Heart Association (AHA) Hypertension Category From Baseline to Week 30

    Distribution of participants by AHA blood pressure classification category at Week 30 compared with baseline.

    Time frame: baseline and Week 30

  25. Shift in American Heart Association (AHA) Hypertension Category From Baseline to Week 21

    Distribution of participants by AHA blood pressure classification category at Week 21 compared with baseline.

    Time frame: baseline and Week 21

  26. Shift in American Diabetes Association (ADA) Glycemia Category From Baseline to Week 30

    Distribution of participants by ADA glycemia classification category at Week 30 compared with baseline.

    Time frame: baseline and Week 30

  27. Shift in American Diabetes Association (ADA) Glycemia Category From Baseline to Week 21

    Distribution of participants by ADA glycemia classification category at Week 21 compared with baseline.

    Time frame: baseline and Week 21

  28. Change From Baseline in Blood Pressure-Lowering Medications (Dose Changes) at Week 30

    Distribution of dose changes (increase, decrease, no change) of blood pressure-lowering medications at Week 30 compared with baseline.

    Time frame: baseline and Week 30

  29. Change From Baseline in Blood Pressure-Lowering Medications (Number) at Week 30

    number of blood pressure-lowering medications at Week 30 compared with baseline.

    Time frame: baseline and Week 30

  30. Change From Baseline in Blood Pressure-Lowering Medications (Number) at Week 21

    number of blood pressure-lowering medications at Week 21 compared with baseline.

    Time frame: baseline and Week 21

  31. Change From Baseline in Blood Pressure-Lowering Medications (Dose Change) at Week 21

    Distribution of dose changes (increase, decrease, no change) of blood pressure-lowering medications at Week 21 compared with baseline.

    Time frame: baseline and Week 21

  32. Change From Baseline in Glucose-Lowering Medications (Dose Changes) at Week 30

    Distribution of dose changes (increase, decrease, no change) of glucose-lowering medications at Week 30 compared with baseline.

    Time frame: baseline and Week 30

  33. Change From Baseline in Glucose-Lowering Medications (Dose Changes) at Week 21

    Distribution of dose changes (increase, decrease, no change) of glucose-lowering medications at Week 21 compared with baseline.

    Time frame: Baseline, Week 21

  34. Change From Baseline in Glucose-Lowering Medications (Number) at Week 30

    number of glucose-lowering medications at Week 30 compared with baseline.

    Time frame: Baseline, Week 30

  35. Change From Baseline in Glucose-Lowering Medications (Number) at Week 21

    number of glucose-lowering medications at Week 21 compared with baseline.

    Time frame: baseline and Week 21

  36. Percentage of Participants With Normalization of 24-Hour Urinary Free Cortisol (UFC) Over Time

    Normalization status of 24-hour UFC for each participant at each scheduled visit, defined as UFC \<=1x the upper limit of normal (ULN).

    Time frame: up Week 30

  37. Percentage of Participants With Blood Pressure Response by 24-Hour ABPM at Week 21

    Blood pressure (BP) responder status is assessed by 24-hour ABPM. A participant is a responder if mean systolic and/or diastolic BP decreases by at least 5 mmHg from baseline, without worsening of either and without any modification in antihypertensive medication attributable to worsening hypertension.

    Time frame: Week 21

07

Study locations

3 of 3 sites recruiting
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for May 2028, 21 months after the start.

Of 35 industry-sponsored phase 4 interventional studies under Hypertension, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's planned 21 months is close to that.

Counting every sponsor, half of 161 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2025
First posted
Nov 25, 2025
StartActual
Aug 26, 2026
Primary completionEst.
May 2028
CompletionEst.
Jul 2028
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 28, 2026
Sites
3 sites added — first site in United States
Show 3 added (3 United States)
  • NOLA Care, LLC · Jacksonville, United States
  • Diabetes And Endocrinology Associates Of Stark County, Inc. · Canton, United States
  • Texas Valley Clinical Research · Weslaco, United States
Oct 28, 2026
Eligibility
6 exclusion criteria edited, 1 added, 1 removed
What changed in the criteria
Exclusion criteria
  • EditedHistory of cyclic Cushing's SyndromeCS with fluctuating clinical manifestations
  • AddedParticipants who have undergone pituitary or adrenal surgery for Cushing's syndrome within 3 months prior to screening.
  • EditedParticipants who are shift workers or have conditions that can affect the measurement of late -night salivary cortisol (LNSC) or the LDDST
  • EditedPoorly controlled diabetes mellitus with a baseline HbA1c > 10.5%. Participants receiving glucose lowering medications must be on stable doses for at least 4 weeks prior screening.
  • RemovedPoorly controlled BP defined as: Average SBP ≥ 170 or average DBP ≥ 110 mmHg as measured by the 24h ABPM
  • EditedHistory of major surgery/surgical therapy for any cause within 1 month4 weeks before entering the study. Participants should have recovered from the surgery and be in good clinical condition before entering the study
  • EditedParticipation in any clinical investigation within 4 weeks prior to screening or longer if required by local regulation (Use of an investigational drug within 1 month4 weeks prior to dosing)
  • EditedOccurrence of any significant acute illness within the three3 weeks prior to dosing/randomisation
Oct 28, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedTo evaluate the efficacy of osilodrostat on the proportion of participants with normalisationnormalization of urinary-free cortisol (UFC)Time frame: 30 weeks
Oct 28, 2026
Secondary outcomes
30 added, 7 more
What changed in the outcomes
  • AddedPercentage of Participants With Blood Pressure Response by 24-Hour Ambulatory Blood Pressure Monitoring (ABPM) at Week 30 (key secondary)Time frame: Week 30
  • AddedPercentage of Participants With Hypocortisolism-Related Adverse Events (Overall)Time frame: Week 30
  • AddedPercentage of Participants With Glucocorticoid Withdrawal SyndromeTime frame: Week 30
  • AddedPercentage of Participants With Confirmed Adrenal InsufficiencyTime frame: Week 30
  • AddedPercentage of Participants With Glycemic Response at Week 30 in Participants With High-Risk DysglycemiaTime frame: baseline and Week 30
  • AddedPercentage of Participants With Glycemic Response at Week 21 in Participants With High-Risk DysglycemiaTime frame: Baseline and Week 21
  • AddedPercentage of Participants With Body Weight Response at Week 30Time frame: baseline and Week 30
  • AddedPercentage of Participants With Body Weight Response at Week 21Time frame: baseline and Week 21
  • AddedChange From Baseline in Systolic Blood Pressure (SBP) by 24-Hour ABPM at Week 30Time frame: Baseline, Week 30
  • AddedChange From Baseline in Systolic Blood Pressure (SBP) by 24-Hour ABPM at Week 21Time frame: baseline and Week 21
  • AddedChange From Baseline in Glucose AUC During OGTT at Week 30 in Participants With High-Risk DysglycemiaTime frame: baseline and Week 30
  • AddedChange From Baseline in Glucose AUC During OGTT at Week 21 in Participants With High-Risk DysglycemiaTime frame: baseline and Week 21
  • AddedChange From Baseline in Glycated Hemoglobin (HbA1c) at Week 30 in Participants With High-Risk DysglycemiaTime frame: baseline and Week 30
  • AddedChange From Baseline in Glycated Hemoglobin (HbA1c) at Week 21 in Participants With High-Risk DysglycemiaTime frame: baseline and Week 21
  • AddedChange From Baseline in 2-Hour Postprandial Glucose at Week 30 in Participants With High-Risk DysglycemiaTime frame: Baseline, Week 30
  • AddedChange From Baseline in 2-Hour Postprandial Glucose at Week 21 in Participants With High-Risk DysglycemiaTime frame: baseline and Week 21
  • AddedChange From Baseline in Fasting Plasma Glucose Over Time in Participants With High-Risk DysglycemiaTime frame: Up to Week 30
  • AddedChange From Baseline in Body Weight Over TimeTime frame: Up to Week 30
  • AddedParticipants (n) With Adverse EventsTime frame: Up to Week 30
  • AddedParticipants (%) With Adverse EventsTime frame: Up to Week 30
  • AddedChange From Baseline in Laboratory ValuesTime frame: Up to Week 30
  • AddedChange From Baseline in Electrocardiogram (ECG) ParametersTime frame: Up to Week 30
  • AddedChange From Baseline in Vital SignsTime frame: Up to Week 30
  • AddedShift in American Heart Association (AHA) Hypertension Category From Baseline to Week 30Time frame: baseline and Week 30
  • AddedShift in American Heart Association (AHA) Hypertension Category From Baseline to Week 21Time frame: baseline and Week 21
  • AddedShift in American Diabetes Association (ADA) Glycemia Category From Baseline to Week 30Time frame: baseline and Week 30
  • AddedShift in American Diabetes Association (ADA) Glycemia Category From Baseline to Week 21Time frame: baseline and Week 21
  • AddedChange From Baseline in Blood Pressure-Lowering Medications (Dose Changes) at Week 30Time frame: baseline and Week 30
  • AddedChange From Baseline in Blood Pressure-Lowering Medications (Number) at Week 30Time frame: baseline and Week 30
  • AddedChange From Baseline in Blood Pressure-Lowering Medications (Number) at Week 21Time frame: baseline and Week 21
  • …and 7 more, on the record history on ClinicalTrials.gov ↗
Oct 28, 2026
Site contacts
Changed at 3 sites. See the sites
Show 3 sites
  • NOLA Care, LLC · Jacksonville, United StatesContact removed (no phone or email listed)
  • Diabetes And Endocrinology Associates Of Stark County, Inc. · Canton, United StatesContact removed (no phone or email listed)
  • Texas Valley Clinical Research · Weslaco, United StatesContact removed (no phone or email listed)
Nov 2, 2026
Show all 2 updates
  1. Nov 2, 2026
    Site contacts Changed at 3 sites. See the sites
    Show 3 sites
    • NOLA Care, LLC · Jacksonville, United StatesContact removed (no phone or email listed)
    • Diabetes And Endocrinology Associates Of Stark County, Inc. · Canton, United StatesContact removed (no phone or email listed)
    • Texas Valley Clinical Research · Weslaco, United StatesContact removed (no phone or email listed)
  2. Oct 28, 2026
    Not yet recruiting→Recruiting
    3 sites added — first site in United States
    Show 3 added (3 United States)
    • NOLA Care, LLC · Jacksonville, United States
    • Diabetes And Endocrinology Associates Of Stark County, Inc. · Canton, United States
    • Texas Valley Clinical Research · Weslaco, United States
    Eligibility 6 exclusion criteria edited, 1 added, 1 removed
    What changed in the criteria
    Exclusion criteria
    • EditedHistory of cyclic Cushing's SyndromeCS with fluctuating clinical manifestations
    • AddedParticipants who have undergone pituitary or adrenal surgery for Cushing's syndrome within 3 months prior to screening.
    • EditedParticipants who are shift workers or have conditions that can affect the measurement of late -night salivary cortisol (LNSC) or the LDDST
    • EditedPoorly controlled diabetes mellitus with a baseline HbA1c > 10.5%. Participants receiving glucose lowering medications must be on stable doses for at least 4 weeks prior screening.
    • RemovedPoorly controlled BP defined as: Average SBP ≥ 170 or average DBP ≥ 110 mmHg as measured by the 24h ABPM
    • EditedHistory of major surgery/surgical therapy for any cause within 1 month4 weeks before entering the study. Participants should have recovered from the surgery and be in good clinical condition before entering the study
    • EditedParticipation in any clinical investigation within 4 weeks prior to screening or longer if required by local regulation (Use of an investigational drug within 1 month4 weeks prior to dosing)
    • EditedOccurrence of any significant acute illness within the three3 weeks prior to dosing/randomisation
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedTo evaluate the efficacy of osilodrostat on the proportion of participants with normalisationnormalization of urinary-free cortisol (UFC)Time frame: 30 weeks
    Secondary outcomes 30 added, 7 more
    What changed in the outcomes
    • AddedPercentage of Participants With Blood Pressure Response by 24-Hour Ambulatory Blood Pressure Monitoring (ABPM) at Week 30 (key secondary)Time frame: Week 30
    • AddedPercentage of Participants With Hypocortisolism-Related Adverse Events (Overall)Time frame: Week 30
    • AddedPercentage of Participants With Glucocorticoid Withdrawal SyndromeTime frame: Week 30
    • AddedPercentage of Participants With Confirmed Adrenal InsufficiencyTime frame: Week 30
    • AddedPercentage of Participants With Glycemic Response at Week 30 in Participants With High-Risk DysglycemiaTime frame: baseline and Week 30
    • AddedPercentage of Participants With Glycemic Response at Week 21 in Participants With High-Risk DysglycemiaTime frame: Baseline and Week 21
    • AddedPercentage of Participants With Body Weight Response at Week 30Time frame: baseline and Week 30
    • AddedPercentage of Participants With Body Weight Response at Week 21Time frame: baseline and Week 21
    • AddedChange From Baseline in Systolic Blood Pressure (SBP) by 24-Hour ABPM at Week 30Time frame: Baseline, Week 30
    • AddedChange From Baseline in Systolic Blood Pressure (SBP) by 24-Hour ABPM at Week 21Time frame: baseline and Week 21
    • AddedChange From Baseline in Glucose AUC During OGTT at Week 30 in Participants With High-Risk DysglycemiaTime frame: baseline and Week 30
    • AddedChange From Baseline in Glucose AUC During OGTT at Week 21 in Participants With High-Risk DysglycemiaTime frame: baseline and Week 21
    • AddedChange From Baseline in Glycated Hemoglobin (HbA1c) at Week 30 in Participants With High-Risk DysglycemiaTime frame: baseline and Week 30
    • AddedChange From Baseline in Glycated Hemoglobin (HbA1c) at Week 21 in Participants With High-Risk DysglycemiaTime frame: baseline and Week 21
    • AddedChange From Baseline in 2-Hour Postprandial Glucose at Week 30 in Participants With High-Risk DysglycemiaTime frame: Baseline, Week 30
    • AddedChange From Baseline in 2-Hour Postprandial Glucose at Week 21 in Participants With High-Risk DysglycemiaTime frame: baseline and Week 21
    • AddedChange From Baseline in Fasting Plasma Glucose Over Time in Participants With High-Risk DysglycemiaTime frame: Up to Week 30
    • AddedChange From Baseline in Body Weight Over TimeTime frame: Up to Week 30
    • AddedParticipants (n) With Adverse EventsTime frame: Up to Week 30
    • AddedParticipants (%) With Adverse EventsTime frame: Up to Week 30
    • AddedChange From Baseline in Laboratory ValuesTime frame: Up to Week 30
    • AddedChange From Baseline in Electrocardiogram (ECG) ParametersTime frame: Up to Week 30
    • AddedChange From Baseline in Vital SignsTime frame: Up to Week 30
    • AddedShift in American Heart Association (AHA) Hypertension Category From Baseline to Week 30Time frame: baseline and Week 30
    • AddedShift in American Heart Association (AHA) Hypertension Category From Baseline to Week 21Time frame: baseline and Week 21
    • AddedShift in American Diabetes Association (ADA) Glycemia Category From Baseline to Week 30Time frame: baseline and Week 30
    • AddedShift in American Diabetes Association (ADA) Glycemia Category From Baseline to Week 21Time frame: baseline and Week 21
    • AddedChange From Baseline in Blood Pressure-Lowering Medications (Dose Changes) at Week 30Time frame: baseline and Week 30
    • AddedChange From Baseline in Blood Pressure-Lowering Medications (Number) at Week 30Time frame: baseline and Week 30
    • AddedChange From Baseline in Blood Pressure-Lowering Medications (Number) at Week 21Time frame: baseline and Week 21
    • …and 7 more, on the record history on ClinicalTrials.gov ↗
    + 5 other changes: identifiers, verification date, date precision, design details and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07247162
Lead sponsor
RECORDATI GROUP
Responsible party
Sponsor
First posted
Nov 25, 2025
Start date
Aug 26, 2026
Primary completion
May 2028 (estimated)
Completion
Jul 2028 (estimated)
Last update
Nov 2, 2026

Study contacts

Michal Sarnecki
Contact
sarnecki.m@recordati.com
+41 (0)79 911 79 87
Mario Maldonado
Contact
maldonado.m@recordati.com
+41 (0)79 803 03 44
Irina Bancos, MD
study chair · Mayo Clinic (Rochester, Minnesota , US)

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Osilodrostat

Start the discussion